Sealable secondary packaging for pharmaceutical product blister pack

ABSTRACT

A pharmaceutical product supply is disclosed in the form of a container, a pharmaceutical product receiver, pharmaceutical product, an adhesive, and at least one release liner. The pharmaceutical product receiver includes a plurality of receptacles for pharmaceutical product. The container is initially disposed in a first configuration where all of the pharmaceutical product receiver receptacles may be accessible. The container is thereafter disposable in a second configuration where no covering for any of the pharmaceutical product receiver receptacles is accessible through any openable access incorporated by the container. One or more release liners may be moved to expose adhesive for disposing and retaining the container in its second configuration. The noted second configuration of the container facilitates disposal of the pharmaceutical product supply (e.g., now being in a form that should reduce the potential for gaining access to any remaining pharmaceutical product still enclosed within the pharmaceutical product receiver).

CROSS-REFERENCE TO RELATED APPLICATIONS

This patent application is a divisional patent application of U.S.patent application Ser. No. 13/103,247, filed on May 9, 2011(now U.S.Pat. No. 8,342,331, issued on Jan. 1, 2013), which is a non-provisionalapplication of U.S. Provisional Patent Application Ser. No. 61/333,174,entitled “SEALABLE SECONDARY PACKAGING FOR PHARMACEUTICAL PRODUCTBLISTER PACK,” and filed on May 10, 2010. The entire disclosure of eachof the above-noted patent applications is incorporated by referenceherein, and priority is claimed to each of the above-noted patentapplications.

FIELD OF THE INVENTION

The present invention generally relates to the field of packaging forpharmaceutical products such as pills, capsules, patches, and the likeand, more particularly, to packaging configurations that facilitate thedisposal of pharmaceutical products (e.g., to reduce the potential ofillicit usage of unused pharmaceutical product).

BACKGROUND

Abuse, misuse, and overdose of pharmaceutical products (e.g., painmanagement drugs) are serious health concerns that affect many people ona daily basis all over the world. For instance, diversion and subsequentmisuse or abuse may occur when a patient gets a prescription for apharmaceutical product and does not use all of the pharmaceuticalproduct for whatever reason (e.g., a doctor may prescribe apharmaceutical product for a patient and advise the patient to take thepharmaceutical product on an “as needed” basis; a patient may be advisedto use an entire prescribed amount of pharmaceutical product, but mayunilaterally decide to discontinue use of the pharmaceutical product asone or more symptoms disappear). In any case, remaining pharmaceuticalproduct may be ultimately acquired by an individual other than for whomthe pharmaceutical product was originally prescribed (e.g., transferredby the original patient to another individual, such as family member orfriend; stolen). While unused pharmaceutical product may be disposed ofin the trash, this may not be viewed by some as a secure method ofdisposal.

In the case of transdermal analgesic patches, a used patch may stillretain a significant amount of active ingredient in the patch. A usedpatch can be very dangerous and can even lead to death for people whohave not been prescribed the patch. While some patch manufacturersrecommend flushing used patches down the toilet, this practice hasraised concerns about drug product entering the water supply. In somestates, “take back” programs have been instituted, allowing users torequest shipping materials in order to ship used or unusedpharmaceutical product (e.g., patches, pills, capsules) to a certifieddisposal company. These programs are costly and require several actionsby the patient at multiple times.

SUMMARY

The present invention embodies a pharmaceutical product supply. Thispharmaceutical product supply includes a container, a pharmaceuticalproduct receiver, pharmaceutical product, an adhesive, and a releaseliner. More specifically, the pharmaceutical product receiver includes aplurality of pockets or receptacles. Each receptacle includes anopening, and at least one covering is disposed over the opening of atleast one the receptacles. Pharmaceutical product is enclosed within atleast one of these receptacles by its corresponding covering. Theadhesive is provided on the container, on the pharmaceutical productreceiver, or on each of the container and the pharmaceutical productreceiver. The release liner is positioned over the adhesive. Thecontainer is initially disposed in a first configuration where thecovering for at least one of the pharmaceutical product receiverreceptacles is accessible. The container is thereafter disposable in asecond configuration where the covering for none of the pharmaceuticalproduct receiver receptacles is accessible through any openable accessincorporated by the container. The release liner is moved to expose theadhesive for disposing and retaining the container in its secondconfiguration (where none of the pharmaceutical product receiverreceptacles are accessible through any openable access incorporated bythe container).

A number of feature refinements and additional features are applicableto the present invention. These feature refinements and additionalfeatures may be used individually or in any combination. As such, eachof the following features that will be discussed may be, but are notrequired to be, used with any other feature or combination of featuresof the present invention. Generally, the container may be of aconfiguration and the adhesive may be incorporated in a manner such thatmoving the release liner to expose the adhesive may accommodate securing(e.g., locking via cured adhesive) the pharmaceutical product receiverwithin the container, for instance to facilitate disposal of thepharmaceutical supply at a time when some of the pharmaceutical productmay have been removed from the pharmaceutical product receiver, butprior to utilizing all of the pharmaceutical product originally providedwith the pharmaceutical product receiver. That is, the noted secondconfiguration of the container may be characterized as facilitatingdisposal of the pharmaceutical product supply (e.g., now being in a formthat should reduce the potential for gaining access to any remainingpharmaceutical product enclosed within the pharmaceutical productreceiver). At the time of disposal, typically one or more of thepharmaceutical product receiver receptacles will be empty (thepharmaceutical product having been previously removed therefrom), whileat least one of the receptacles will still have pharmaceutical productenclosed therein.

The opening for each receptacle may be characterized as being disposedon a common side of the pharmaceutical product receiver. In the “asdispensed” configuration, the opening of each receptacle may be blockedby a corresponding covering (e.g., pharmaceutical product may beenclosed within each receptacle). At this time, the container may be inits first configuration. Although the container could also be disposedin its second configuration (where the covering for none of thereceptacles is accessible through any openable access incorporated bythe container) with the opening of each receptacle still being blockedby its corresponding covering, more typically pharmaceutical productwill have been removed from at least one of the receptacles. As such, itwill more typically be the case that the covering associated with atleast one of the receptacles will also have been removed or otherwiseruptured, torn, ripped, pierced, or the like to allow removal of thepharmaceutical product for such a receptacle(s) at the time thecontainer is disposed in its second configuration.

The container may be characterized as a “secondary packaging,” while thepharmaceutical product receiver may be characterized as “primarypackaging.” The pharmaceutical product receiver may be in the form of ablister card or blister packaging. Scoring or perforations could beprovided between each adjacent pair of receptacles of the blister card.As such, a single “blister pack” could be removed from the remainder ofthe blister card and for any appropriate reason.

The above-noted blister card may be in the form of a pre-formed tray orthe like having a number of receptacles or pockets. Any appropriatenumber of receptacles may be incorporated by the blister card. Thevarious receptacles may be disposed in any appropriate arrangement, forinstance in the form of a matrix having a certain number of rows and acertain number of columns at the time the blister card is dispensed to apatient or other end user.

An appropriate covering may be positioned over each receptacle in theabove-noted blister card tray to enclose the associated pharmaceuticalproduct. Such a covering may be in the form of a film, a foil, paper, asheet-like material, or the like. In any case, this covering may besecured to the tray in any appropriate manner to seal pharmaceuticalproduct within each of the various receptacles (e.g., a singlepharmaceutical product dose). In one embodiment, this covering isrupturable over each of the individual receptacles of the tray to gainaccess to the pharmaceutical product within the receptacle. Rupturingthe covering that overlies one receptacle should not affect the coveringover any of the other receptacles (e.g., pharmaceutical product in theseother receptacles should remain enclosed within the tray by thecovering). In another embodiment, the covering may be “peeled” away fromat least part of the tray to expose pharmaceutical product in at leastone receptacle. Although a single covering could be positioned over eachof the various receptacles, individual coverings could be positionedover each individual receptacle.

The adhesive may be incorporated only on the container, or only on thepharmaceutical product receiver. The adhesive may also be incorporatedby each of the container and the pharmaceutical product receiver. Onerelease liner may be provided for the adhesive on the container, andanother release liner may be provided for the adhesive on thepharmaceutical product receiver. Any appropriate adhesive may be used.

The container may be of a variety of different configurations tofacilitate the disposal of unused pharmaceutical product still containedwithin the pharmaceutical product receiver. In one embodiment, thecontainer is in the form of a tri-fold carton or a three-paneledstructure (in one embodiment the container includes only three panels).Consider the case where the container includes first, second, and thirdpanels, with the second panel being located between the first and thirdpanels. One boundary region may exist at the intersection between thefirst and second panels (e.g., a “fold line” at the intersection betweenthe first and second panels). Another boundary region may exist betweenthe second and third panels (e.g., a “fold line” at the intersectionbetween the second and third panels).

The pharmaceutical product receiver may be incorporated by the secondpanel of a three-paneled container in any appropriate manner (e.g.,positioned or mounted on a first side of this second panel). Each of thefirst and third panels may be configured so as to not incorporate anyopenable access (e.g., no openable cover/lid/flap included in either ofthe first or third panels; no perforations or scoring included in eitherof the first or third panels for defining an openable cover/lid/flap;such that no covering for any receptacle of the pharmaceutical productreceiver is accessible when the container is disposed in its secondconfiguration). A first adhesive may be provided on all or a portion ofa surface or side of the first panel that is disposable in interfacingrelation with the pharmaceutical product receiver (e.g., the side of thereceiver through which the receptacles may be accessed to retrievepharmaceutical product—the side with one or more coverings). A firstrelease liner may be provided for this first adhesive. A second adhesivemay be provided on all or a portion of a surface or a side of the thirdpanel that is disposable in interfacing relation with a second side ofthe second panel (opposite of the side that includes the pharmaceuticalproduct receiver). A second release liner may be provided for the secondadhesive. The first and second release liners may be removed from thecorresponding adhesive, the first panel may be folded onto and mayadhere to the pharmaceutical product receiver, and the third panel maybe folded onto and may adhere to the opposite side of the second panel.In one embodiment, the first and third panels are pivoted in the samegeneral direction (e.g., in an end view of the container, in a commonclockwise or counterclockwise direction) to secure the pharmaceuticalproduct receiver between the first and third panels. The pharmaceuticalproduct supply may be in the form of a stack when folded and adhesivelyjoined in the above-noted manner. This particular three-paneledconfiguration may itself be an independent aspect of the presentinvention.

The pharmaceutical product receiver may itself be the second panel of athree-paneled container. Each of the first and third panels may beconfigured so as to not incorporate any openable access (e.g., noopenable cover/lid/flap included in either of the first or third panels;no perforations or scoring included in either of the first or thirdpanels for defining an openable cover/lid/flap; such that no coveringfor any receptacle of the pharmaceutical product receiver is accessiblewhen the container is disposed in its second configuration). A firstadhesive may be provided on all or a portion of a surface or side of thefirst panel that is disposable in interfacing relation with a first sideof the pharmaceutical product receiver (e.g., the side of the receiverthrough which the receptacles may be accessed to retrieve pharmaceuticalproduct—the side with one or more coverings). A first release liner maybe provided for this first adhesive. A second adhesive may be providedon all or a portion of a surface or side of the third panel that isdisposable in interfacing relation with an oppositely disposed secondside of the pharmaceutical product receiver. A second release liner maybe provided for the second adhesive. The first and second release linersmay be moved away from the corresponding adhesive, the first panel maybe folded onto and may adhere to the first side of the pharmaceuticalproduct receiver, and the third panel may be folded onto and may adhereto the second side of the pharmaceutical product receiver. In oneembodiment, the first and third panels are pivoted in the same generaldirection (e.g., in an end view of the container, in a common clockwiseor counterclockwise direction) to secure the pharmaceutical productreceiver between the first and third panels. The pharmaceutical productsupply may be in the form of a stack when folded and adhesively joinedin the above-noted manner. This particular three-paneled configurationmay itself be an independent aspect of the present invention.

Regardless of whether the pharmaceutical product receiver is separatelyattached to or functions as the second panel of the noted three-paneledcontainer, a number of observations apply. One is that thepharmaceutical product receiver may be “sandwiched” between the firstand third panels and should be retained in a stack with the first andthird panels by adhesive. As neither the first nor third panels includeany openable access (e.g., no openable cover/lid/flap included in eitherof the first or third panels; no perforations or scoring included ineither of the first or third panels for defining an openablecover/lid/flap; such that no covering for any receptacle of thepharmaceutical product receiver is accessible at this time), thepharmaceutical product receiver should be rendered at leastsubstantially inaccessible at this time (e.g., the first panel may beadhered to the side of the pharmaceutical product receiver thatincorporates the openings to its various receptacles). Anotherobservation is that pharmaceutical product information, labeling, or thelike that may be incorporated on the pharmaceutical product receivershould remain hidden from viewing when the pharmaceutical productreceiver is “sandwiched” between and adhered to (directly or indirectly)the first and third panels. One or both of these features should reducethe potential that the pharmaceutical product supply will be “removedfrom the trash” for purposes of attempting to retrieve unusedpharmaceutical product.

The container for the pharmaceutical product supply may be a two-paneledstructure (in one embodiment the container includes only two panels). A“fold line” may exist at an intersection between first and secondpanels. The pharmaceutical product receiver may be incorporated by thesecond panel in any appropriate manner, and the first panel itself maybe configured so as to not incorporate any openable access (e.g., noopenable cover/lid/flap included in the first panel; no perforations orscoring included in the first panel for defining an openablecover/lid/flap). The pharmaceutical product receiver could define thesecond panel. The pharmaceutical product receiver could be separatelymounted to the second panel (e.g., via an appropriate adhesive). Thesecond panel could also include an internal storage area thataccommodates multiple pharmaceutical product receivers, with an openingthereto facing the first panel when closed onto the second panel. In anycase, a first adhesive may be provided on all or a portion of a surfaceor side of the first panel that is disposable in interfacing relationwith a side of the second panel that includes or that provides access tothe pharmaceutical product receiver. A first release liner may beprovided for this first adhesive. A second adhesive may be provided onall or part of a surface or side of the second panel that includes orthat provides access to the pharmaceutical product receiver (e.g., theside of the receiver through which the receptacles may be accessed toretrieve pharmaceutical product—the side with one or more coverings),and that is disposable in interfacing relation with the first panel. Asecond release liner may be provided for the second adhesive. In thecase where the pharmaceutical product receiver is mounted to the secondpanel, the second disposal adhesive may be disposed on a part of thesecond panel that extends about the perimeter of the pharmaceuticalproduct receiver. Either of the first and second adhesives could be used(i.e., only one of the adhesives may be required), or each of the firstand second adhesives could be used. In any case, once the relevantrelease liner(s) is removed from the corresponding adhesive, the firstpanel may be folded onto and may adhere to that side of the second panelthat includes or that provides access to the pharmaceutical productreceiver (e.g., the side of the receiver through which the receptaclesmay be accessed to retrieve pharmaceutical product—the side with one ormore coverings). As the container does not include any openable accessafter being disposed in this configuration (e.g., no openablecover/lid/flap; no perforations or scoring included by the container fordefining an openable cover/lid/flap; such that no covering for anyreceptacle of the pharmaceutical product receiver is accessible at thistime), the pharmaceutical product receiver should be rendered at leastsubstantially inaccessible at this time (e.g., the first panel may beadhered to the side pharmaceutical product receiver that incorporatesthe openings to its various receptacles). This particular two-paneledconfiguration may itself be an independent aspect of the presentinvention.

Another two-paneled configuration may be used as the container for thepharmaceutical product supply (in one embodiment the container includesonly two panels). A boundary region may exist at an intersection betweenfirst and second panels (e.g., a “fold line” at an intersection betweenthe first and second panels). In any case, the pharmaceutical productreceiver may be incorporated by the second panel in any appropriatemanner. The pharmaceutical product receiver could define the secondpanel. The pharmaceutical product receiver could be separately mountedto the second panel (e.g., via an appropriate adhesive). The secondpanel could also include an internal storage area that accommodatesmultiple pharmaceutical product receivers, with an opening theretofacing the first panel when closed onto the second panel. In any case,adhesive may be provided on all or a portion of a surface or side of thefirst panel that is disposable in interfacing relation with the side ofthe second panel that includes or that provides access to thepharmaceutical product receiver (e.g., the side of the receiver throughwhich the receptacles may be accessed to retrieve pharmaceuticalproduct—the side with one or more coverings). The release liner in thiscase is disposed over the adhesive, and furthermore is attached to thefirst panel at a location that is spaced from the boundary regionbetween the first and second panels (e.g., on an opposite end of thefirst panel in relation to that which may adjoin the second panel). Inthis case and once the release liner is moved away from the adhesive,the first panel may be folded onto and may adhere to that side of thesecond panel that includes or that provides access to the pharmaceuticalproduct receiver (e.g., the side of the receiver through which thereceptacles may be accessed to retrieve pharmaceutical product—the sidewith one or more coverings). The first panel, or at least the releaseliner that now extends therefrom, may be wrapped around an end sectionof the second panel (which could simply be an edge, although it could bea surface of any appropriate contour), and in any case may be adhered tothe side of the second panel that is opposite that which includes orthat provides access to the pharmaceutical product receiver. As thecontainer does not include any openable access after being disposed inthis configuration (e.g., no openable cover/lid/flap; no perforations orscoring included by the container for defining an openablecover/lid/flap; such that no covering for any receptacle of thepharmaceutical product receiver is accessible at this time), thepharmaceutical product receiver should be rendered at leastsubstantially inaccessible at this time. This particular two-paneledconfiguration may itself be an independent aspect of the presentinvention.

Another multi-paneled configuration may be used as the container for thepharmaceutical product supply. A boundary region may exist at anintersection between first and second panels (e.g., a “fold line” at anintersection between the first and second panels). In any case, thepharmaceutical product receiver may be incorporated by the second panelin any appropriate manner. The pharmaceutical product receiver coulddefine the second panel. The pharmaceutical product receiver could beseparately mounted to the second panel (e.g., via an appropriateadhesive). The second panel could also include an internal storage areathat accommodates multiple pharmaceutical product receivers, with anopening thereto facing the first panel when closed onto the secondpanel.

The first panel may actually be in the form of first and second panelsections in this embodiment. One end of the first panel section may beseparated from the second panel by a boundary region (e.g., a foldline). An opposite and free end of the first panel section may beseparated from its end that may adjoin the second panel section. Thesecond panel section may be folded onto the first panel section.Adhesive may be provided on all or a portion of the surfaces of thefirst and second panel sections that are disposable in interfacingrelation (e.g., that may be folded onto one another). One or morerelease liners in this case may be disposed over the adhesive on the twonoted surfaces of the first and second panel sections. The second panelsection may be moved away from the first panel section (e.g., to movethe first panel toward or into an extended configuration). Each releaseliner for the adhesive on the first and second panel sections may bemoved to expose the adhesive. The first panel section may be folded ontoand may adhere to that side of the second panel that includes or thatprovides access to the pharmaceutical product receiver (e.g., the sideof the receiver through which the receptacles may be accessed toretrieve pharmaceutical product—the side with one or more coverings).The first panel section, or the second panel section that now extendstherefrom, may be wrapped around an end section of the second panel(which could simply be an edge, although it could be a surface of anyappropriate contour). At least part of the second panel section may beadhered to the side of the second panel that is opposite that whichincludes or that provides access to the pharmaceutical product receiver.As the container does not include any openable access after beingdisposed in this configuration (e.g., no openable cover/lid/flap; noperforations or scoring included by the container for defining anopenable cover/lid/flap; such that no covering for any receptacle of thepharmaceutical product receiver is accessible at this time), thepharmaceutical product receiver should be rendered at leastsubstantially inaccessible at this time. This particular two-paneledconfiguration may itself be an independent aspect of the presentinvention.

Another option is for the container to include an internal storage area,along with an opening that provides access to this internal storage areaand a cover that selectively blocks this opening. One or morepharmaceutical product receivers they be positioned within this internalstorage area. The cover may include the adhesive and the release liner.Once this release liner is removed and the cover is adhered to a portionof the container body so as to selectively block the opening, and as thecontainer does not include any openable access after being disposed inthis configuration (e.g., no openable cover/lid/flap; no perforations orscoring included by the container for defining an openablecover/lid/flap; such that no covering for any receptacle of thepharmaceutical product receiver is accessible at this time), thepharmaceutical product receiver should be rendered at leastsubstantially inaccessible at this time.

Yet another option is for the container to include first and secondpanels that are disposed in spaced relation, an internal storage areabetween the first and second panels, and an opening that provides accessto this internal storage area. An inner surface of at least one of thefirst and second panels may include adhesive and a corresponding releaseliner. This particular configuration may itself be an independent aspectof the present invention. In any case, the release liner may “doubleback” on itself. Consider the case where one end of the release liner ispositioned on or adjacent to the start of the adhesive. The releaseliner may extend toward a closed end of the container and in overlyingrelation to the adhesive, and then “double back” on itself toward theopening of the container. In one embodiment, the “doubling back” sectionof the release liner extends through and beyond the opening of thecontainer for grasping by a patient or other user. Once the releaseliner is removed, the container may be disposed in a configuration wherethe covering for none of the plurality of receptacles is accessiblethrough any openable access of the container.

Consider the case where only the interior surface of the first panelincludes adhesive and the noted “doubling back” release liner. When therelease liner is removed in this case, the side of the pharmaceuticalproduct receiver that incorporates the openings for its variousreceptacles may be disposed in interfacing relation with this adhesiveto bond this side of the pharmaceutical product receiver to the interiorsurface of the first panel. As the first panel does not include anyopenable access (e.g., no openable cover/lid/flap; no perforations orscoring included in the first panel for defining an openablecover/lid/flap; such that no covering for any receptacle of thepharmaceutical product receiver is accessible at this time), thepharmaceutical product receiver should be rendered at leastsubstantially inaccessible at this time. If the container is formed soas to not be easily ruptured, torn, or the like, either side of thepharmaceutical product receiver could be bonded to the interior surfaceof the first panel to become bonded within the interior of the containerand rendered at least substantially inaccessible (e.g., such that nocovering for any receptacle of the pharmaceutical product receiver isaccessible at this time).

Now consider the case where the interior surface of each of the firstand second panels includes adhesive and a corresponding “doubling back”release liner. When the two release liners are removed in this case anda single pharmaceutical product receiver is disposed within the interiorof the container, the first and second panels may be pressed together toadhere this single pharmaceutical product receiver therebetween (e.g.,to define a stack, with the pharmaceutical product receiver beinginteriorly disposed within the stack, such that any remainingpharmaceutical product is at least substantially inaccessible). Asneither the first nor second panel includes any openable access (e.g.,no openable cover/lid/flap included in either of the first or secondpanels; no perforations or scoring included in either of the first orsecond panels for defining an openable cover/lid/flap; such that nocovering for any receptacle of the pharmaceutical product receiver isaccessible at this time), the single pharmaceutical product receiverwithin this bonded stack should be rendered at least substantiallyinaccessible at this time.

If two pharmaceutical product receivers are within a container thatutilizes two doubling back release liners in accordance with theforegoing, and both release liners are removed, the side of onepharmaceutical product receiver that incorporates the openings for itsvarious receptacles may be disposed in interfacing relation withadhesive to bond this side of the pharmaceutical product receiver to theinterior surface of the first panel, and the side of the secondpharmaceutical product receiver that incorporates the openings for itsvarious receptacles may be disposed in interfacing relation withadhesive to bond this side of the pharmaceutical product receiver to theinterior surface of the second panel. As neither the first nor secondpanels include any openable access (e.g., no openable cover/lid/flapincluded in either of the first or second panels; no perforations orscoring included in either of the first or second panels for defining anopenable cover/lid/flap; such that no covering for any receptacle of thepharmaceutical product receiver is accessible at this time), the twopharmaceutical product receivers bonded within the interior of thecontainer should be rendered at least substantially inaccessible. If thecontainer is formed so as to not be easily ruptured, torn, or the like,either side of each pharmaceutical product receiver could be bonded tothe interior surface of the corresponding first or second panel tobecome bonded within the interior of the container and rendered at leastsubstantially inaccessible (e.g., such that no covering for anyreceptacle of the pharmaceutical product receiver is accessible at thistime).

Any feature of any other various aspects of the present invention thatis intended to be limited to a “singular” context or the like will beclearly set forth herein by terms such as “only,” “single,” “limitedto,” or the like. Merely introducing a feature in accordance withcommonly accepted antecedent basis practice does not limit thecorresponding feature to the singular (e.g., indicating that apharmaceutical product supply includes “a pharmaceutical productreceiver” alone does not mean that the pharmaceutical product supplyincludes only a single pharmaceutical product receiver). Moreover, anyfailure to use phrases such as “at least one” also does not limit thecorresponding feature to the singular (e.g., indicating thatpharmaceutical product supply includes “a pharmaceutical productreceiver” alone does not mean that the pharmaceutical product supplyincludes only a single pharmaceutical product receiver). Use of thephrase “at least generally” or the like in relation to a particularfeature encompasses the corresponding characteristic and insubstantialvariations thereof (e.g., indicating that a panel is at least generallyflat encompasses the panel being flat). Finally, a reference of afeature in conjunction with the phrase “in one embodiment” does notlimit the use of the feature to a single embodiment.

A “pharmaceutical product” as used herein may generally define anymaterial or substance used in the course of a medical treatment, medicaldiagnosis, therapy, or the provision of any other appropriate medicalcare. A given material need not contain an active drug compound oringredient to be considered a “pharmaceutical product” for purposes ofthe present invention. In one embodiment, each pharmaceutical product isin the form of a pill (e.g., a tablet or capsule).

A pharmaceutical product within the receptacles of the pharmaceuticalproduct receiver may be in any appropriate form, in any appropriatedose, and of any appropriate type. A pharmaceutical product encompassesboth a single-dose configuration (e.g., a single pill) and a multipledose configuration (e.g., a plurality of pills). Pharmaceutical productmay be in any appropriate form such as (but not limited to) pills,tablets, chewables, capsules, or the like. Further, a “pharmaceuticalproduct” may refer to or include any “drug” as defined in Title 21 ofthe United States Code, Section 321(g)(1).

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1A is a top view of a representative blister card.

FIG. 1B is a side view of the blister card of FIG. 1A.

FIG. 1C is an end view of the blister card of FIG. 1A.

FIG. 2 is an end view of one embodiment of a pharmaceutical productsupply that utilizes a three-panel structure that may seal apharmaceutical product receiver between a pair of panels to facilitatedisposal.

FIG. 3 is a perspective view of one embodiment of a pharmaceuticalproduct supply that utilizes a two-panel structure that may seal apharmaceutical product receiver between a pair of panels to facilitatedisposal.

FIGS. 4A-C are sequential end views of one embodiment of apharmaceutical product supply that utilizes another two-panel structurethat may seal a pharmaceutical product receiver between a pair of panelsto facilitate disposal.

FIGS. 5A-B are sequential perspective views of one embodiment of apharmaceutical product supply that utilizes a sealable carton that maybe adhesively sealed to enclose a pharmaceutical product receiver tofacilitate disposal.

FIG. 6A-C are sequential views of one embodiment of a pharmaceuticalproduct supply that utilizes a carton with an internally-disposedadhesive to secure a pharmaceutical product receiver therein tofacilitate disposal.

FIG. 6D-E are sequential views of a variation of the embodiment of FIGS.6A-C.

FIGS. 7A-C are sequential end views of a variation of the pharmaceuticalproduct supply of FIGS. 4A-C.

DETAILED DESCRIPTION

A representative blister card or pack is shown in FIGS. 1A, 1B, and 1C,and is identified by reference numeral 10. The blister card 10 includesa tray 12 (e.g., a pre-formed structure, for instance plastic) having aplurality of receptacles 18. Any number of receptacles 18 may beutilized by the tray 12, and these receptacles 18 may be disposed in anyappropriate arrangement. In the illustrated embodiment, there are tworows and five columns of receptacles 18. Any number of rows and columnsmay be utilized. Any arrangement of receptacles 18 may be utilized bythe blister card 10.

Pharmaceutical product 30 may be disposed in each receptacle 18 of theblister card 10, and as such the blister card 10 may be referred to as“primary packaging” for the pharmaceutical product 30. A covering 20 isdisposed over each receptacle 18 to enclose the correspondingpharmaceutical product 30 (the covering 20 being “puckered” in FIGS. 1Band 1C to distinguish the same from the tray 12, although the covering20 could be at least substantially coplanar with the upper surface 14 ofthe tray 12). Although a single covering could extend over an entiretyof an upper surface 14 of the tray 12 (or at least over each of thevarious receptacles 18), in the illustrated embodiment each receptacle18 has its own individual covering 20. Any covering 20 for the blistercard 10 may be in the form of a film, foil, paper, a sheet-likematerial, or the like. Generally, pharmaceutical product 30 may beremoved from a given receptacle 18 by pushing on a lower surface 16 ofthe tray 12 (more specifically a receptacle 18), which in turn may pushthe pharmaceutical product 30 against the associated covering 20 with asufficient force so as to rupture the covering 20. The covering 20 couldalso be “peeled” away from the tray 12 to gain access to pharmaceuticalproduct 30 within a receptacle 18. Any way of gaining access to thepharmaceutical product 30 in a given receptacle 18, enclosed by acovering 20, may be implemented by the blister card 10.

Each receptacle 18 may be characterized as having a correspondingopening 22. The covering 20 for a corresponding receptacle 18 may becharacterized as blocking this opening 22 (e.g., to enclosepharmaceutical product 30 within the corresponding receptacle 18). Inthe illustrated embodiment, the opening 22 for each receptacle 18 isdisposed on a common side of the tray 12, namely its upper surface 14.

Blister cards 10 may be utilized by various pharmaceutical productssupplies to be addressed herein (e.g., a combination of secondarypackaging of a variety of configurations, together with one or moreblister cards 10 (e.g., primary packaging)). Each of these embodimentsis directed to a pharmaceutical product supply that includes acontainer, a pharmaceutical product receiver, pharmaceutical product, anadhesive, and at least one release liner. The pharmaceutical productreceiver includes a plurality of pockets or receptacles, andpharmaceutical product may be enclosed within each of these receptacles.The adhesive is provided on the container, on the pharmaceutical productreceiver, or on each of the container and the pharmaceutical productreceiver, and a release liner is positioned over the adhesive. Thecontainer is initially disposed in a first configuration where at leastone (including all) of the pharmaceutical product receiver receptaclesare accessible. The container is thereafter disposable in a secondconfiguration where none of the pharmaceutical product receiverreceptacles are accessible through any openable access incorporated bythe container. One or more release liners may be moved to expose theadhesive for disposing and retaining the container in its secondconfiguration (where none of the pharmaceutical product receiverreceptacles are accessible through any openable access incorporated bythe container). The noted second configuration of the containerfacilitates disposal of the pharmaceutical product supply (e.g., nowbeing in a form that should reduce the potential for gaining access toany remaining pharmaceutical product still enclosed within thepharmaceutical product receiver). At the time of disposal, typically oneor more of the pharmaceutical product receiver receptacles will be empty(the pharmaceutical product having been previously removed therefrom),while at least one of the receptacles will still have pharmaceuticalproduct enclosed therein.

One embodiment of such a pharmaceutical product supply is illustrated inFIG. 2 and is identified by reference numeral 40. The pharmaceuticalproduct supply 40 includes a container 42 in the form of a three-paneledstructure (only three panels in the illustrated embodiment). Thecontainer 42 includes a first panel 44, a second panel 48, and a thirdpanel 52. The second panel 48 is located between the first panel 44 andthe third panel 52. A boundary region 64 (e.g., an intersection or foldline) exists between the first panel 44 and the second panel 48. Aboundary region 66 (e.g., an intersection or fold line) exists betweenthe second panel 48 and the third panel 52.

The second panel 48 may incorporate a blister card 10 in any appropriatemanner. In the illustrated embodiment, the blister card 10 functions asthe second panel 48. However, a blister card 10 could also be separatelyattached or mounted to the second panel 48. Each of the first panel 44and the third panel 52 are configured so as to not incorporate anyopenable access (e.g., no openable cover/lid/flap included in either ofthe first or third panels 44, 52; no perforations or scoring included ineither of the first or third panels 44, 52 for defining an openablecover/lid/flap).

The first panel 44 includes a first surface 46 a and an oppositelydisposed second surface 46 b. A first adhesive 56 is provided on atleast part of the first surface 46 a of the first panel 44. A firstrelease liner 58 is provided for the first adhesive 56. The third panel52 includes a first surface 54 a and an oppositely disposed secondsurface 54 b. A second adhesive 60 is provided on at least part of thefirst surface 54 a of the third panel 52. A second release liner 62 isprovided for the second adhesive 60. Prior to removing the releaseliners 58, 62, the first panel 44 may be pivoted in the directionindicated by the corresponding arrow in FIG. 2 and the third panel 52may be pivoted in the direction indicated by the corresponding arrow inFIG. 2 to dispose the container 42 in a configuration for storing theblister card 10 between dosing events.

The release liners 58, 62 may be removed from the corresponding adhesive56, 60 in preparation for disposal of the blister card 10 (e.g., todispose the container 42 in a configuration for disposal with unusedpharmaceutical product 30 remaining in one or more blister cards 10).With the first release liner 58 being moved away from the first surface46 a of the first panel 44, the first panel 44 may be pivoted in thedirection indicated by the associated arrow so that its first surface 46a comes into contact with one side of the second panel 48 (the side ofthe second panel 48 that includes a lower surface 16 of the tray 12 ofthe blister card 10 in the illustrated configuration). With the secondrelease liner 62 being moved away from the first surface 54 a of thethird panel 52, the third panel 52 may be pivoted in the directionindicated by the associated arrow so that its first surface 54 a comesinto contact with an opposite side of the second panel 48 (the side ofthe second panel 48 that includes the upper surface 14 of the tray 12 ofthe blister card 10 in the illustrated configuration; the side of theblister card 10 that includes the one or more coverings 20). As thecontainer 42 does not include any openable access after being disposedin this configuration (e.g., no openable cover/lid/flap; no perforationsor scoring included by the container 42 for defining an openablecover/lid/flap; such that no covering 20 for any receptacle 18 of theblister card 10 is accessible at this time), the blister card 10 shouldbe rendered at least substantially inaccessible at this time.

Bonding the third panel 52 to the side of the blister card 10 thatincludes the openings 22 (and any remaining coverings 20; e.g., itsupper surface 14) in the above-noted manner, should reduce the potentialof pharmaceutical product 30 thereafter being removed from the blistercard 10 (e.g., such that no covering 20 for any receptacle 18 of theblister card 10 is accessible at this time). Bonding the third panel 52and bonding the first panel 44 to opposite sides of the blister card 10,and in the above-noted manner, disposes the blister card 10 within theinterior of a stack (e.g., collectively, the first panel 44, the secondpanel 48, and the third panel 52), which should reduce the potential ofpharmaceutical product 30 thereafter being removed from the blister card10 (e.g., such that no covering 20 for any receptacle 18 of the blistercard 10 is accessible at this time).

Another embodiment of a pharmaceutical product supply is illustrated inFIG. 3 and is identified by reference numeral 70 (only two panels in theillustrated embodiment). The pharmaceutical product supply 70 includes acontainer 72 in the form of a two-paneled structure. The container 72includes a first panel 74 and a second panel 78. An intersection or foldline 90 exists between the first panel 74 and the second panel 78.

The first panel 74 includes a first surface 76. A first adhesive 82 isincluded on all or part of this first surface 76. A first release liner84 is disposed over the first adhesive 82. The first panel 74 isconfigured so as to not incorporate any openable access (e.g., noopenable cover/lid/flap included in the first panel 74; no perforationsor scoring included in the first panel 74 for defining an openablecover/lid/flap).

The second panel 78 may accommodate a blister card 10 in any appropriatemanner. For instance, a blister card 10 could be separately attached tothe second panel 78. The second panel 78 could also be in the form of ahollow structure or the like that includes an internal storage area toaccommodate one or more blister cards 10 (e.g., and that may be accessedby an opening which may coincide with the intersection between theperimeter of the blister card 10 and the second panel 78 in the viewshown in FIG. 3). In any case, all or part of a perimeter region 92 on asurface 80 of the second panel 78 may include a second adhesive 86. Asecond release liner 88 is disposed over the second adhesive 86.Although both adhesives 82, 86 may be utilized and as illustrated inFIG. 3, it may be possible to only utilize one of the adhesives 82, 86.Prior to removing the release liners 84, 88, the first panel 74 may bepivoted in the direction indicated by the corresponding arrow in FIG. 3to dispose the container 72 in a configuration for storing one or moreblister cards 10 between dosing events.

The release liners 84, 88 may be moved away from the correspondingadhesive 82, 86 in preparation for disposal of the associated blistercard(s) 10 (e.g., to dispose the container 72 in a configuration fordisposal with unused pharmaceutical product 30 remaining in one or moreblister cards 10). With the first release liner 84 being moved away fromthe first surface 76 of the first panel 74, and with the second releaseliner 88 being moved away from the first surface 80 of the second panel78, the first panel 74 may be pivoted in the direction indicated by theassociated arrow so that its first surface 76 comes into contact with atleast the perimeter region 92 of the second panel 78 (the side of thesecond panel 78 that includes or provides access to at least one blistercard 10 in the illustrated configuration; the side of the blister card10 that includes the one or more coverings 20). As the container 72 doesnot include any openable access after being disposed in thisconfiguration (e.g., no openable cover/lid/flap; no perforations orscoring included by the container 72 for defining an openablecover/lid/flap; such that no covering 20 for any receptacle 18 of theblister card 10 is accessible at this time), the blister card 10 shouldbe rendered at least substantially inaccessible at this time.

Bonding the first panel 74 to the side of the blister card 10 thatincludes the openings 22 (and any remaining coverings 20; e.g., itsupper surface 14), bonding the first panel 74 to the perimeter region92, or both, should reduce the potential of pharmaceutical product 30thereafter being removed from any blister card 10 within or incorporatedby the container 72 (e.g., such that no covering 20 for any receptacle18 of the blister card 10 is accessible at this time). Bonding the firstpanel 74 in the noted manner disposes one or more blister cards 10within the interior of the container 72, which should reduce thepotential of pharmaceutical product 30 thereafter being removed from anysuch blister card(s) 10 (e.g., such that no covering 20 for anyreceptacle 18 of the blister card 10 is accessible at this time).

Another embodiment of a pharmaceutical product supply is illustrated inFIGS. 4A-C and is identified by reference numeral 100. Thepharmaceutical product supply 100 includes a container 102 in the formof a two-paneled structure. The container 102 includes a first panel 104and a second panel 112. An intersection or fold line 126 may existbetween the first panel 104 and the second panel 112.

The first panel 104 includes a first surface 110. An adhesive 120 isincluded on all or part of this first surface 110. A release liner 122is disposed over the adhesive 120. The first panel 104 may becharacterized as having a pair of oppositely disposed ends 106, 108. Theend 106 is disposed at the intersection 126 with the second panel 112.One end 124 b of the release liner 122 is attached to the first panel104 at or near its free end 108 (more generally, at a location spacedfrom where the first panel 104 adjoins the second panel 112). The otherend 124 a of the release liner 122 is “free” so that the release liner122 may be pulled away from the adhesive 120 on the first surface 110 ofthe first panel 104.

The second panel 112 may accommodate a blister card 10 in anyappropriate manner. For instance, a blister card 10 could be separatelyattached to the second panel 112 (not shown). The second panel 112 couldalso be in the form of a hollow structure or the like that includes aninternal storage area 128 to accommodate one or more blister cards. Afront side 114 of the second panel 112 may include an opening to provideaccess to the internal storage area 128. A back side 116 of the secondpanel 112 is disposed opposite of the front side 114. Prior to movingthe release liner 122 away from the first surface 110 of the first panel104, the first panel 104 (along with the release liner 122) may bepivoted in the direction indicated by the corresponding arrow in FIG. 4Aso as to be disposed in overlying relation to the second panel 112, toin turn dispose the container 102 in a configuration for storing one ormore blister cards 10 between dosing events.

The release liner 122 may be moved to expose the adhesive 120 on thefirst surface 110 of the first panel 104 in preparation for disposal ofthe associated blister card(s) 10 (e.g., to dispose the container 102 ina configuration for disposal with unused pharmaceutical product 30remaining in one or more blister cards 10). A patient or other user maygrab the free end 124 a of the release liner 122 (FIG. 4A) and pull thesame away from the first surface 110 of the first panel 104. However,the release liner 122 extends from and remains attached to the firstpanel 104 (e.g. FIG. 4B). Adhesive 120 may exist on the release liner122 as well. With the first release liner 122 being moved away from thefirst surface 110 of the first panel 104, the first panel 104 may bepivoted in the direction indicated by the associated arrow (FIGS. 4A and4B) so that its first surface to 110 comes into contact with the frontside 114 of the second panel 112 (the side of the second panel 112 thatincludes or provides access to at least one blister card 10 in theillustrated configuration). The release liner 122 (again attached to orextending from first panel 104 at a location spaced from itsintersection 126 with the second panel 112) may be pulled around an endsection 118 of the second panel 112 and may be disposed against andadhered to at least part of the back side 116 of the second panel 112.As the container 102 does not include any openable access after beingdisposed in this configuration (e.g., no openable cover/lid/flap; noperforations or scoring included by the container 102 for defining anopenable cover/lid/flap; such that no covering 20 for any receptacle 18of the blister card 10 is accessible at this time), the blister card 10should be rendered at least substantially inaccessible at this time.

Bonding the first surface 110 of the first panel 104 to the front side114 of the second panel 112, bonding the release liner 122 to the backside 116 of the second panel 112, or both, should reduce the potentialof pharmaceutical product 30 thereafter being removed from any blistercard 10 within or incorporated by the container 102 (e.g., such that nocovering 20 for any receptacle 18 of the blister card 10 is accessibleat this time). Bonding the first surface 110 of the first panel 104 tothe front side 114 of the second panel 112, bonding the release liner122 to the back side 116 of the second panel 112, or both, disposes oneor more blister cards 10 within the interior of the container 102, whichshould reduce the potential of pharmaceutical product 30 thereafterbeing removed from any such blister card 10 (e.g., such that no covering20 for any receptacle 18 of the blister card 10 is accessible at thistime).

Another embodiment of a pharmaceutical product supply is illustrated inFIGS. 5A-B and is identified by reference numeral 130. Thepharmaceutical product supply 130 includes a container 132. A firstpanel 134 and a second panel 136 of the container 132 are disposed inspaced relation (e.g. parallel to one another) and define at least partof an internal storage area 138. The container 132 further includes anopening 140 to provide access to this internal storage area 138. One ormore blister cards 10 may be kept in the internal storage area 138.

The container 132 also includes a cover 142 for selectivelyopening/closing the opening 140. This cover 142 may extend from an endof the second panel 136. A fold line 144 may exist at the intersectionof the cover 142 with the second panel 136.

At least part of the cover 142 includes an adhesive 146. A release liner148 is positioned over the adhesive 146. Prior to removing the releaseliner 148, the cover 142 (along with the release liner 148) may bepivoted in the direction indicated by the corresponding arrow in FIG. 5Asuch that its free end is disposed within the internal storage area 138,to in turn dispose the container 132 in a configuration for storing oneor more blister cards 10 between dosing events.

The release liner 148 may be moved to expose the adhesive 146 on thecover 142 in preparation for disposal of any blister card(s) 10contained within the internal storage area 138 (e.g., to dispose thecontainer 132 in a configuration for disposal with unused pharmaceuticalproduct 30 remaining in one or more blister cards 10). The cover 142 maybe pivoted in the direction indicated by the arrow in FIG. 5A so thatthe cover 142 may be disposed in engagement with and adhered to anexternal side of the first panel 134 of the container 132 (FIG. 5B). Asthe container 132 does not include any openable access after beingdisposed in this configuration (e.g., no openable cover/lid/flap; noperforations or scoring included by the container 132 for defining anopenable cover/lid/flap; such that no covering 20 for any receptacle 18of the blister card 10 is accessible at this time), each blister card 10within the internal storage area 138 should be rendered at leastsubstantially inaccessible at this time.

Bonding the cover 142 to the external side of the first panel 134 (FIG.5B configuration) should reduce the potential of pharmaceutical product30 thereafter being removed from any blister card 10 within orincorporated by the container 132 (e.g., such that no covering 20 forany receptacle 18 of the blister card 10 is accessible at this time).Bonding the cover 142 to the external side of the first panel 134disposes one or more blister cards 10 within the interior of thecontainer 132, which should reduce the potential of pharmaceuticalproduct 30 thereafter being removed from any such blister card(s) 10(e.g., such that no covering 20 for any receptacle 18 of the blistercard 10 is accessible at this time).

Another embodiment of a pharmaceutical product supply is illustrated inFIGS. 6A-C and is identified by reference numeral 150. Thepharmaceutical product supply 150 includes a container 152. A firstpanel 154 and a second panel 156 of the container 152 are disposed inspaced relation (e.g. parallel to one another) and define at least partof an internal storage area 158. The container 152 further includes anopening 170 to provide access to this internal storage area 158. One ormore blister cards 10 may be kept in the internal storage area 158.

Adhesive 160 is included on all or part of an inside wall of the firstpanel 154 (that wall or surface of the first panel 154 which interfaceswith the internal storage area 158). A release liner 162 is positionedover this adhesive 160 (shown in spaced relation in FIG. 6B for clarity,but the release liner 162 will actually be positioned on this adhesive160). Prior to removing the release liner 162, the container 152 is in aconfiguration for storing one or more blister cards 10 between dosingevents.

The release liner 162 may utilize a “doubling-back” configuration.Referring to FIG. 6B, the release liner 162 may extend from one of itsends 164 toward a closed container end 172 of the container 152, and maybe positioned on the adhesive 160. At location 168, the release liner162 “doubles back” toward the container opening 170 where it terminatesat a free end 166. In the illustrated embodiment, the end 164 of therelease liner 162 is located between it free end 166 and the closedcontainer end 172 (in a dimension coinciding with a spacing between thecontainer opening 170 and the closed container end 172). In theillustrated embodiment, the doubling-back portion of the release liner162 extends through and past the container opening 170 such that itsfree end 166 is located outside of the internal storage area 158 of thecontainer 152.

The free end 166 of the release liner 162 may be pulled away from thecontainer 152 so as to expose the adhesive 160 on the inside wall of thefirst panel 154 in preparation for disposal of each blister card 10contained within the internal storage area 158 (e.g., to dispose thecontainer 152 in a configuration for disposal with unused pharmaceuticalproduct 30 remaining in a single blister card 10). This configuration isshown in FIG. 6C. The container 152 thereafter may be compressed in adirection corresponding with the spacing between the first panel 154 andthe second panel 156 (i.e., to reduce the spacing between the firstpanel 154 and second panel 156) so that the blister pack 10 is broughtinto engagement with and adheres to the inside wall or surface of thefirst panel 154. As the container 152 does not include any openableaccess after being disposed in this configuration (e.g., no openablecover/lid/flap; no perforations or scoring included by the container 152for defining an openable cover/lid/flap; such that no covering 20 forany receptacle 18 of the blister card 10 is accessible at this time),the blister card 10 should be rendered at least substantiallyinaccessible at this time.

When the release liner 162 is removed in the case of the container 152of FIGS. 6A-C, the side of the blister card 10 that incorporates theopenings 22 for its various receptacles 18 (and any remaining coverings20; e.g., its upper surface 14) may be disposed in interfacing relationwith the adhesive 160 on the inside wall of the first panel 154 to bondthis side of the blister card 10 to the interior surface of the firstpanel 154 (e.g., such that no covering 20 for any receptacle 18 of theblister card 10 is accessible at this time). Again, FIG. 6C shows theblister card 10 prior to actually being bonded to the inside wall of thefirst panel 154. Bonding the blister card 10 to the first panel 154 inthe noted manner disposes the blister card 10 within the internalstorage area 170 of the container 152, which should reduce the potentialof pharmaceutical product 30 thereafter being removed from such ablister card 10 (e.g., such that no covering 20 for any receptacle 18 ofthe blister card 10 is accessible at this time). If the container 152 isformed so as to not be easily ruptured, torn, or the like, either sideof the blister card 10 could be bonded to the inside wall of the firstpanel 154 to become bonded within the interior of the container 152 andrendered at least substantially inaccessible (e.g., such that nocovering 20 for any receptacle 18 of the blister card 10 is accessibleat this time).

Another embodiment of a pharmaceutical product supply is illustrated inFIGS. 6D-E, is a variation of the pharmaceutical product supply 150 ofFIGS. 6A-C, and is identified by reference numeral 150′. Correspondingcomponents between the embodiment of FIGS. 6A-C and the embodiment ofFIGS. 6D-E are identified by the same reference numeral. Thosecorresponding components that differ in at least some respect areidentified by a “single prime” designation in FIGS. 6D-E. In thisregard, the primary distinction between these embodiments is that thecontainer 152′ in the embodiment of FIGS. 6D-E also includes adhesive160 on the inside wall of the second panel 156, along with acorresponding release liner 162 of the above-noted type/configuration.Each release liner 162 is shown in spaced relation to its correspondingadhesive 160 in FIG. 6D for clarity, but each release liner 162 willactually be positioned on its corresponding adhesive 160.

Consider the case where a single blister card 10 is disposed within thecontainer 152′ and as shown in FIGS. 6D-E. When the two release liners162 are removed in the above-noted manner, the container 152′ may becompressed to dispose each of the two sides of the blister card 10 (itsupper surface 14 and lower surface 16) in interfacing relation with theadjacent inner wall of the panels 154, 156 (e.g., disposes the blistercard 10 within the interior of a stack defined by the first panel 154,the blister card 10, and the second panel 156). Bonding the blister card10 to the inner wall of each of the panels 154, 156 in this mannerdisposes the blister card 10 within the internal storage area 170 of thecontainer 152′, which should reduce the potential of pharmaceuticalproduct 30 thereafter being removed from such a blister card 10 (e.g.,such that no covering 20 for any receptacle 18 of the blister card 10 isaccessible at this time).

If the container 152′ is formed so as to not be easily ruptured, torn,or the like, two blister cards 10 could be contained within thecontainer 152′ when disposed in a configuration for disposal. Eitherside of a first blister card 10 could be bonded to the inside wall ofthe first panel 154 to become bonded within the interior of thecontainer 152′ and rendered at least substantially inaccessible (e.g.,such that no covering 20 for any receptacle 18 of the blister card 10 isaccessible at this time). Either side of second blister card 10 could bebonded to the inside wall of the second panel 156 to become bondedwithin the interior of the container 152′ and rendered at leastsubstantially inaccessible (e.g., such that no covering 20 for anyreceptacle 18 of the blister card 10 is accessible at this time).

Another embodiment of a pharmaceutical product supply is illustrated inFIGS. 7A-C, is identified by reference numeral 100′, and is a variationof the pharmaceutical product supply 100 of FIGS. 4A-C. Correspondingcomponents between these two embodiments are identified by the samereference numeral. Those corresponding components that differ in atleast some respect are identified by a “single prime” designation inFIGS. 7A-C.

The pharmaceutical product supply 100′ includes a container 102′ in theform of a three-paneled structure. The container 102′ includes a firstpanel 104′ and the above-discussed second panel 112. The first panel104′ in this embodiment is actually itself a two-paneledstructure—including a first panel section 104 a and a second panelsection 122′. An intersection or fold line 126 may exist between thefirst panel 104′ and the second panel 112.

The first panel section 104 a includes a first surface 110. An adhesive120 is included on all or part of this first surface 110. The firstpanel section 104 a may be characterized as having a pair of oppositelydisposed ends 106, 108. The end 106 is disposed at the intersection 126with the second panel 112.

Instead of being in the form of a release liner 122 in the case of theembodiment of FIGS. 4A-C, reference numeral 122′ in the embodiment ofFIGS. 7A-C is actually in the form of a second panel section 122′. Allor part of a surface of the second panel section 122′ that may bedisposed in overlying relation to the first panel section 104 a includesadhesive 120. One or more removable release liners 129 may be disposedbetween the adhesive 120 on first panel section 104 a and the secondpanel section 122′.

One end 124 b of the second panel section 122′ is attached to the firstpanel section 104 a at or near its free end 108 (more generally, at alocation spaced from where the first panel section 104 a adjoins thesecond panel 112). The other end 124 a of the second panel section 122′is “free” so that the second panel section 122′ may be pulled away fromthe first surface 110 of the first panel section 104 a. Prior toremoving the release liner(s) 129, the first panel 104′ (along with eachrelease liner 129) may be pivoted in the direction indicated by thearrow A in FIG. 7A so as to be disposed in overlying relation to thesecond panel 112, to in turn dispose the container 102′ in aconfiguration for storing one or more blister cards 10 between dosingevents.

The second panel section 122′ may be moved in the direction of the arrowB in FIG. 7A (e.g., pivoted about a fold line between the first panelsection 104 a and the second panel section 122′) to expose the eachrelease liner 129 (located between the first panel section 104 a and thesecond panel section 122′ when disposed in interfacing or overlyingrelation) in preparation for disposal of the associated blister card(s)10 (e.g., to dispose the container 102′ in a configuration for disposalwith unused pharmaceutical product 30 remaining in one or more blistercards 10). This may be referred to as “opening” the first panel 104′. Apatient or other user may grab the free end 124 a of the second panelsection 122′ (FIG. 7A) and move the same entirely away from the firstsurface 110 of the first panel section 104 a and at least generally inthe direction of the arrow B in FIG. 7A. However, the second panelsection 122′ extends from and remains attached to the first panelsection 104 a (e.g. FIG. 7B). With the second panel section 122′ beingmoved away from the first surface 110 of the first panel section 104 a,the first panel section 104 a may be pivoted in the direction indicatedby the arrow A in FIG. 7A (also depicted by the arrow in FIG. 7B; e.g.,about a fold line between the first panel section 104 a and the secondpanel 112) so that its first surface 110 comes into contact with thefront side 114 of the second panel 112 (the side of the second panel 112that includes or provides access to at least one blister card 10 in theillustrated configuration). The second panel section 122′ (againattached to or extending from first panel section 104 a at a locationspaced from its intersection 126 with the second panel 112) may bepulled around an end section 118 of the second panel 112 and may bedisposed against and adhered to at least part of the back side 116 ofthe second panel 112. As the container 102′ does not include anyopenable access after being disposed in this configuration (e.g., noopenable cover/lid/flap; no perforations or scoring included by thecontainer 102′ for defining an openable cover/lid/flap; such that nocovering 20 for any receptacle 18 of the blister card 10 is accessibleat this time), the blister card 10 should be rendered at leastsubstantially inaccessible at this time.

Bonding the first panel section 104 a of the first panel 104′ to thefront side 114 of the second panel 112, bonding the second panel section122′ to the back side 116 of the second panel 112, or both, shouldreduce the potential of pharmaceutical product 30 thereafter beingremoved from any blister card 10 within or incorporated by the container102′ (e.g., such that no covering 20 for any receptacle 18 of theblister card 10 is accessible at this time). Bonding the first panelsection 104 a of the first panel 104′ to the front side 114 of thesecond panel 112, bonding the second panel section 122′ to the back side116 of the second panel 112, or both, disposes one or more blister cards10 within the interior of the container 102, which should reduce thepotential of pharmaceutical product 30 thereafter being removed from anysuch blister card 10 (e.g., such that no covering 20 for any receptacle18 of the blister card 10 is accessible at this time).

The foregoing description of the present invention has been presentedfor purposes of illustration and description. Furthermore, thedescription is not intended to limit the invention to the form disclosedherein. Consequently, variations and modifications commensurate with theabove teachings, and skill and knowledge of the relevant art, are withinthe scope of the present invention. The embodiments describedhereinabove are further intended to explain best modes known ofpracticing the invention and to enable others skilled in the art toutilize the invention in such, or other embodiments and with variousmodifications required by the particular application(s) or use(s) of thepresent invention. It is intended that the appended claims be construedto include alternative embodiments to the extent permitted by the priorart.

What is claimed:
 1. A pharmaceutical product supply, comprising: a firstpanel and a second panel, wherein said first panel comprises a firstsection and a second section, wherein said first section adjoins saidsecond panel, and wherein said second section is folded onto said firstsection when said pharmaceutical product supply is in a firstconfiguration; a pharmaceutical product receiver associated with saidsecond panel and comprising a plurality of receptacles; pharmaceuticalproduct enclosed within at least one of said plurality of receptacles ofsaid pharmaceutical product receiver; and adhesive between said firstsection of said first panel and said second section of said first panelwhen said pharmaceutical product supply is in said first configuration;wherein said first panel is movable between an open position and aclosed position relative to said second panel to provide access to saidpharmaceutical product receiver when said pharmaceutical product supplyis in said first configuration, and wherein said second section of saidfirst panel is disposed between said second panel and said first sectionof said first panel when said first panel is in said closed position andwhen said pharmaceutical product supply is in said first configuration;and wherein said pharmaceutical product supply is disposable andretained in a second configuration where said second section of saidfirst panel is moved away from said first section of said first panel,where said first section of said first panel is adhered to at least afirst side of said second panel, and where said second section of saidfirst panel is adhered to at least a second side of said second panel,wherein said first side of said second panel and said second side ofsaid second panel are oppositely disposed to one another.
 2. Thepharmaceutical product supply of claim 1, wherein said pharmaceuticalproduct receiver is incorporated on said first side of said secondpanel, wherein said second section of said first panel comprises arelease liner that is attached to said first section of said first panelat a location that is spaced from an intersection between said firstpanel and said second panel, and wherein a surface of said release linerand a surface of said first section of said first panel that face eachother with said pharmaceutical product supply being in said firstconfiguration each comprise said adhesive.
 3. The pharmaceutical productsupply of claim 1, wherein said second section of said first panelcomprises a release liner that is attached to said first section of saidfirst panel at a location that is spaced from an intersection betweensaid first panel and said second panel, wherein a surface of saidrelease liner and a surface of said first section of said first panelthat face each other with said pharmaceutical product supply being insaid first configuration each comprise said adhesive, and wherein saidfirst side of said second panel comprises an opening to an internalstorage area in which said pharmaceutical product receiver is disposed.4. The pharmaceutical product supply of claim 3, further comprising asecond pharmaceutical product receiver within said internal storagearea.
 5. The pharmaceutical product supply of claim 3, wherein a firstend of said first section of said first panel is at said intersectionbetween said first panel and said second panel, and wherein said releaseliner is attached to a second end of said first section of said firstpanel that is opposite of said first end.
 6. The pharmaceutical productsupply of claim 3, wherein at least one of said first section of saidfirst panel and said release liner is also adhered to an end section ofsaid second panel when said pharmaceutical product supply is in saidsecond configuration.
 7. The pharmaceutical product supply of claim 1,wherein said pharmaceutical product receiver is incorporated on saidfirst side of said second panel, wherein said second section of saidfirst panel is attached to said first section of said first panel at alocation that is spaced from an intersection between said first panelsection and said second panel, wherein a surface of said first sectionof said first panel and a surface of said second section of said firstpanel that face each other when said pharmaceutical product supply is insaid first configuration each comprise said adhesive, saidpharmaceutical product supply further comprising: at least one releaseliner between said surface of said first section of said first panel andsaid second section of said first panel that face each other when saidpharmaceutical product supply is in said first configuration.
 8. Thepharmaceutical product supply of claim 1, wherein said pharmaceuticalproduct receiver is incorporated on said first side of said secondpanel, wherein said first side of said second panel comprises an openingto an internal storage area in which said pharmaceutical productreceiver is disposed, wherein said second section of said first panel isattached to said first section of said first panel at a location that isspaced from an intersection between said first section of said firstpanel and said second panel, wherein a surface of said first section anda surface of said second section of said first panel that face eachother when said pharmaceutical product supply is in said firstconfiguration each comprise said adhesive, said pharmaceutical productsupply further comprising: at least one release liner between saidsurface of said first section of said first panel and said secondsection of said first panel that face each other when saidpharmaceutical product supply is in said first configuration.
 9. Thepharmaceutical product supply of claim 8, further comprising a secondpharmaceutical product receiver within said internal storage area. 10.The pharmaceutical product supply of claim 8, wherein a first end ofsaid first section of said first panel is at said intersection betweensaid first panel and said second panel, and wherein said second sectionof said first panel is attached to a second end of said first section ofsaid first panel that is opposite of said first end.
 11. Thepharmaceutical product supply of claim 8, wherein at least one of saidfirst section of said first panel and said second section of said firstpanel is also adhered to an end section of said second panel when saidpharmaceutical product supply is in said second configuration.
 12. Thepharmaceutical product supply of claim 1, wherein each said receptaclecomprises an opening, each receptacle of said plurality of receptaclesthat includes said pharmaceutical product having a correspondingcovering over its corresponding said opening, and wherein no saidcorresponding covering for any of said plurality of receptacles isaccessible through any operable access on said first panel when saidpharmaceutical product supply is disposed and retained in said secondconfiguration.
 13. A pharmaceutical product supply, comprising: firstpanel and a second panel, wherein said first panel comprises a surfacehaving an adhesive, wherein a release liner is attached to said firstpanel at a location that is spaced from an intersection between saidfirst panel and said second panel, and wherein said release linercomprises a surface having an adhesive; a pharmaceutical productreceiver associated with said second panel and comprising a plurality ofreceptacles; and pharmaceutical product enclosed within at least one ofsaid plurality of receptacles of said pharmaceutical product receiver;wherein said first panel is movable between an open position and aclosed position relative to said second panel to provide access to saidpharmaceutical product receiver when said pharmaceutical product supplyis in a first configuration where said surface of said release linerhaving said adhesive is positioned over said surface of said first panelhaving said adhesive; and wherein said pharmaceutical product supply isdisposable and retained in a second configuration where said releaseliner is moved away from said first panel, where said first panel isadhered to at least a first side of said second panel, and where saidrelease liner is adhered to at least a second side of said second panel,wherein said first side of said second panel and said second side ofsaid second panel are oppositely disposed to one another.
 14. Thepharmaceutical product supply of claim 13, wherein said pharmaceuticalproduct receiver is incorporated on said first side of said secondpanel.
 15. The pharmaceutical product supply of claim 13, wherein saidfirst side of said second panel comprises an opening to an internalstorage area in which said pharmaceutical product receiver is disposed.16. The pharmaceutical product supply of claim 15, further comprising asecond pharmaceutical product receiver within said internal storagearea.
 17. The pharmaceutical product supply of claim 13, wherein a firstend of said first panel is at said intersection between said first paneland said second panel, and wherein said release liner is attached to asecond end of said first panel that is opposite of said first end. 18.The pharmaceutical product supply of claim 13, wherein at least one ofsaid first panel and said release liner is also adhered to an endsection of said second panel when said pharmaceutical product supply isin said second configuration.
 19. The pharmaceutical product supply ofclaim 13, wherein each said receptacle comprises an opening, eachreceptacle of said plurality of receptacles that includes saidpharmaceutical product having a corresponding covering over itscorresponding said opening, wherein no said corresponding covering forany of said plurality of receptacles is accessible through any openableaccess on said first panel when said pharmaceutical product supply isdisposed and retained in said second configuration.